Skip to main content

Table 2 Health economic outcomes

From: An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

Outcome Unadjusted (PAS) Adjusted (MVAS)
Daptomycin (n = 118) Vancomycin (n = 106) P value Rate ratiob P value
IRLOS, hours, mean (SD) 91.5 (57.8) 93.2 (60.8) 0.823 1.002 (0.844–1.191) 0.979
Total LOS, hours, mean (SD) 98.5 (77.0) 101.2 (72.1) 0.785 1.018 (0.861–1.204) 0.833
Total inpatient cost, 2012 US$, mean (SD)a 9641 (6683) 9083 (5855) 0.509 0.940 (0.803–1.101) 0.442
  1. IRLOS infection-related length of stay, LOS length of stay, MVAS multivariate analytic sample, PAS primary analytic sample, SD standard deviation
  2. aWholesale acquisition cost estimates using “waste” algorithm
  3. bRate ratio reflects effect of vancomycin relative to daptomycin on outcome of interest. Ratios reported as mean (95 % confidence interval)